GSK plc has completed its previously announced acquisition of IDRx Inc., a Boston-based, clinical-stage biopharmaceutical ...

GSK completes acquisition of Boston-based, clinical-stage biopharma company, IDRx, Inc.

GSK (GSK) plc announced that it has completed the acquisition of IDRx, Inc., a Boston-based, clinical-stage biopharmaceutical company dedicated ...

IDRX-42, originally licensed from MSD in 2022. IDRX-42 is a selective tyrosine kinase inhibitor (TKI) designed to treat gastrointestinal stromal tumours (GIST) by targeting all major KIT mutations ...

That pipeline is led by IDRX-42, a highly selective KIT tyrosine kinase inhibitor (TKI) that is being developed as a first- and second-line therapy for gastrointestinal stromal tumour (GIST ...

and completed a $120 million Series B last August to fund clinical development of lead cancer drug candidate IDRX-42, which hiked its valuation to around $430 million. The company had also been ...

The acquisition includes lead molecule, IDRX-42, a highly selective KIT TKI being developed as a first- and second-line therapy for the treatment of GIST. GIST typically presents in the GI tract with ...

GSK on Monday also said it has start the GBP2 billion buyback programme that it announced earlier this month, starting with an initial GBP700 million tranche.

The acquisition includes lead molecule IDRX-42, a highly selective KIT tyrosine kinase inhibitor (TKI) being developed to treat GIST. 'IDRX-42 complements our growing portfolio in gastrointestinal ...

The deal centers around IDRx's leading drug candidate, IDRX-42, which is a highly selective KIT tyrosine kinase inhibitor (TKI) in development as a treatment for GIST in both first- and second-line ...

GSK plc (LSE/NYSE: GSK) today announced that it has completed the acquisition of IDRx, Inc. (IDRx), a Boston-based, ...